Free Trial
NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

MaxCyte logo
$2.71 -0.02 (-0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$2.70 0.00 (-0.18%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MaxCyte Stock (NASDAQ:MXCT)

Key Stats

Today's Range
$2.64
$2.76
50-Day Range
$2.73
$5.10
52-Week Range
$2.62
$5.26
Volume
485,752 shs
Average Volume
517,462 shs
Market Capitalization
$287.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67
Consensus Rating
Buy

Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Remove Ads

MaxCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

MXCT MarketRank™: 

MaxCyte scored higher than 52% of companies evaluated by MarketBeat, and ranked 539th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MaxCyte has only been the subject of 2 research reports in the past 90 days.

  • Read more about MaxCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MaxCyte is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MaxCyte is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MaxCyte has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about MaxCyte's valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of MaxCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    MaxCyte has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in MaxCyte has recently increased by 10.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MaxCyte does not currently pay a dividend.

  • Dividend Growth

    MaxCyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of MaxCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    MaxCyte has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in MaxCyte has recently increased by 10.37%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MaxCyte has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MaxCyte this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $61,235.00 in company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of MaxCyte is held by insiders.

  • Percentage Held by Institutions

    68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MaxCyte's insider trading history.
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock News Headlines

MaxCyte Expands Capital with New Stock Issuance
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
BTIG Reaffirms Their Buy Rating on MaxCyte (MXCT)
See More Headlines

MXCT Stock Analysis - Frequently Asked Questions

MaxCyte's stock was trading at $4.16 at the beginning of the year. Since then, MXCT stock has decreased by 35.1% and is now trading at $2.7010.
View the best growth stocks for 2025 here
.

MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative trailing twelve-month return on equity of 16.00%.

MaxCyte (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/06/2024
Today
4/01/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
NASDAQ:MXCT
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+217.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,920,000.00
Pretax Margin
-78.37%

Debt

Sales & Book Value

Annual Sales
$38.63 million
Price / Cash Flow
N/A
Book Value
$2.23 per share
Price / Book
1.22

Miscellaneous

Free Float
102,671,000
Market Cap
$289.46 million
Optionable
Optionable
Beta
1.35
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MXCT) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners